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A B S T R A C T
This is a first cross-sectional study on the prevalence and distribution of HPV infection in asymptomatic, heterosex-
ual men from Osijek-Baranja County, Croatia. Between 2009 and 2011, 330 men tested for sexually transmitted diseases
(STDs) were recruited. Their genital swabs were tested for high-risk HPV (HR HPV) infection by the AMPLICOR HPV
test and further genotyped by the Linear Array HPV Genotyping Test (both by Roche). Infection with a single HR HPV
was detected in almost one third of men (39%) whereas multiple HPV types, in more than a half of HR HPV-positive men
(61%). The highest HR HPV prevalence was detected in those younger than 20 (37.5%) and lowest in 31–35 year old men
(27.8%). The most common genotypes were HPV 6 (24%), 16 (17.8%), 51 (9%), 52 (6%), 35, 55, 66, 84 (each 5%), 31, 62
(each 4%), 39, 58, 59, 83 (each 2.5%), and finally 56, 18, 53, and 54 (each 1.3%). Having more than one sexual partner per
year was significantly associated with HR HPV infection in age group between 26 and 30 years (p=0.001). Due to the
high prevalence of HR HPV infection in men of this County and its risk of transmission to women, we recommend more
public awareness about this particular STD and initiating vaccination programs of young men and women.
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Introduction
Genital infection with the human papilloma virus
(HPV) is a common sexually transmitted disease (STD).
Out of 118 known HPV types, more than 40 affect the
genitals and specifically 8 of them called the high-risk
HPVs (HR HPVs) cause almost all cervical cancers. In
Croatia with a population of 4.4 million, 355 newly cases
of cervical cancers are registered each year1.
Genital HR HPV infections in men, however, are of-
ten asymptomatic and rarely cause malignancies. For ex-
ample, in Osijek-Baranja County, when compared to 362
cases of cervical cancer, only 11, 29 or 44 cases of the
HPV-related anal, penile, and oropharyngeal cancers re-
spectively were reported in men between 1998 and 2011
(Epidemiology Department, Institution of Public Health
of the Osijek-Baranja County, unpublished). Because HR
HPV infections are asymptomatic in the majority of men,
they get unknowingly transmitted to women and this is a
major cause of concern2,3.
Prophylactic programs are one solution to reduce the
prevalence of HR HPV infections. In Australia, the im-
plementation of a routine and government-funded vacci-
nation of 12-year old girls since 2007 diminished the inci-
dence of HPV-related genital warts and is expected to
dramatically reduce HR HPV infection in both women
and men4. Furthermore, HPV vaccination of young men
has now been proposed. In Croatia, however, the quadri-
valent recombinant vaccine against HPVs 6, 11, 16 and
18 (Gardasil) has been rarely used: no men and only 50
women were immunized against HPV in Osijek-Baranja
County between 2007 and 2011 (Epidemiology Depart-
ment, Institute of Public Health, Osijek, 2011).
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There is a lack of information on HPV infection prev-
alence and genotype distribution in men. When com-
pared to similar studies done in women, the epidemiol-
ogy and pathogenesis of HR HPV infection in Croatian
men have been less investigated5–7 and not at all in men
from Osijek-Baranja County, Croatia. Our objective was
thus to report on HPV infection prevalence and genotype
distribution in men from north-east Croatia.
In this work, genital swabs of 416 sexually active and
mostly asymptomatic men from Osijek-Baranja County
who attended an STD testing between 2009 and 2011
were analysed for HPV. A sensitive, Federal Drug Admin-
istration (FDA)-approved polymerase chain reaction
(PCR)-based assay was employed to detect for 15 HR
HPVs, 3 intermediate risk HPVs (IR HPV) and 19 low-
-risk HPV types (LR HPVs). We hope that our evidence
of a relatively high HR HPV prevalence among men in
north-east Croatia (32%), including their high rate of
multiple HPV infections (61%), will increase public awa-
reness especially among men and initiate vaccination
programs for young women and men.
Methods
Study design and population
This cross-sectional study included 416 sexually ac-
tive and mostly asymptomatic men from Osijek-Baranja
County tested for sexually transmitted diseases (STDs)
between March 2009 and December 2011. The mean age
of participants was 32±7.9 years (ages 17 to 60). In-
formed consent was obtained from all HR HPV analyzed
patients. Participants completed a questionnaire that in-
cluded questions on marital and socio-economic status,
education level, sexual and smoking habits. Eight incom-
plete questionnaires were excluded from the statistical
analyses of lifestyle risk factors associated with HPV
genital infection. The Ethics Committee of the Institute
of Public Health of Osijek-Baranja County approved the
study.
Genital samples for HPV testing
Genital wet swabs were collected either at our depart-
ment at the Institute of Public Health of Osijek-Baranja
County (216 samples, collected from the entire genital
areas) or at outpatient clinics by general practitioners or
other medical specialists (200 samples, collected mainly
from urethral canals). Samples were stored in the Micro-
Test M4RT transport medium (Remel, USA) until fur-
ther analysis.
Detection and genotyping of HPV
DNA isolation from 416 genital swabs was performed
with the High Pure PCR Template Kit (Roche Diagnos-
tics GmbH, Germany). HR HPV presence was deter-
mined by the AMPLICOR HPV test (Roche Diagnostics
GmbH, Germany) that detects 13 HR HPV genotypes
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). Suc-
cessful b-globin amplification served as DNA quality
control. Genital specimens PCR negative for b-globin
(86/416) were excluded from further analysis of HR HPV
prevalence and risk factors for HPV infection. DNA from
HR HPV positive specimens was stored at –20 °C until
more detailed HPV typing. Out of 106 HR HPV-positive
genital swabs, 47 were referred to our department for
HPV genotyping by their general practitioners. Geno-
type was determined using the Linear Array HPV Detec-
tion and Linear Array Genotyping test (Roche Diagnos-
tics GmbH, Germany) that detects 15 HR HPVs (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), 3 IR
HPVs (26, 53, 66) and 19 LR HPVs (6, 11, 40, 42, 54, 55,
61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, IS39 and CP6108)
genotypes. DNA isolation and amplification were per-
formed according to the manufacturer’s specifications.
HPV prevalence and statistical analysis
HR HPV prevalence was expressed as a percentage of
HR HPV-positive samples against 330 genital swabs that
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TABLE 1
STATISTICAL ANALYSIS OF POTENTIAL RISK FACTORS FOR HR











21–25 24 42 66 0.8759
26–30 28 67 95
31–35 20 52 72
36–40 15 26 41
³41 16 32 48
Current smoking
Yes 40 51 91 0.8405
No 105 122 227
No. of cigarettes/day
£5 12 38 50 0.2356
6–19 18 29 47
³20 16 46 62
Marital status
Unmarried 40 103 143 0.7434
Married 53 122 173
No. of sex partners/year
0 6 12 18 0.594
1 82 172 254
>1 15* 22 37
Condom use
Yes 16 37 53 0.8437
No 87 179 266
Monthly income
<500 51 100 151 0.9252
500–1000 43 95 138
1000–1500 6 12 18
>1500 4 6 10
*(c2=3.37; p=0.053)
passed quality control. Male participants in this study
were classified according their age into six groups: under
20 (8 participants), 21–25 (66 participants), 26–30 (95
participants), 31–35 (72 participants), 36–40 (41 partici-
pants) and older than 40 (48 participants) years. Age-
-specific prevalence of different LR and HR HPV geno-
types was calculated using the Microsoft Office Excel
2003 software (Microsoft). Multivariate analyses of age,
HR HPV or various HPV genotypes in relation to possi-
ble lifestyle risk factors for genital infection with HPV
were calculated using MedCalc 10.2 (MedCalc Software)
and Statistica 8.0 (StatSoft). Analyses of risk factors ex-
cluded a number of subjects because of incomplete ques-
tionnaires (Tables 1 and 2). Results were considered sig-
nificant for p values <0.05.
Results
HR HPV prevalence
Between March 2009 and December 2011, one third
(106/330) of study participants whose genital swabs pas-
sed the PCR quality control (330/416) was infected with
HR-HPV. Figure 1 shows that the highest infection rate,
37.5% (3/8), was found in men younger than 20 years.
Similar rates were observed in majority of other age cate-
gories: from 36.6% (15/41) in 36–40 year old men to
36.4% (24/66) in 21–25 year old men. The lowest HR
HPV prevalence was observed in 31–35 years old men
(27.8% i.e. 20/72). Finally, there was no statistically sig-
nificant association between age and HR HPV preva-
lence.
Distribution of HPV Genotypes in HR-HPV
infected men
Out of 47 HR HPV-positive genital swabs, 87.2%
(41/47) were successfully genotyped while 12.3% (6/47)
were positive for an unclassified HPV type. These unclas-
sified specimens were PCR positive for b-globin gene and
PCR negative for any of 37 HPVs due to insufficient
amount of HPV DNA. Figure 2 shows that HPV 6 was
the most prevalent genotype in HR HPV-infected men
(24.2%). This was followed by HPV 16 (17.8%), HPV 51
(8.8%), HPV 52 (6.4%), HPVs 35, 55, 66 and 84 (5%
each), HPVs 31 and 62 (3.8% each), HPVs 39, 58, 59, 83
(2.5% each), and HPVs 56, 18, 53 and 54 (1.3% each).
Age-specific distribution of different HPV genotypes
is presented in Figure 3. HPVs 6 and 51 were mostly de-
tected in 26–30 year old men 10/19 (52.6%) and 4/8
(50%), whereas HPV 16 was mostly detected in 31–35
year old men 7/15 (46.6%). Interestingly, some genotypes
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TABLE 2
AGE-SPECIFIC HPV INFECTION IN RELATION TO THE NUMBER OF SEXUAL PARTNERS PER YEAR
Age groups/years
0 sex partner per year 1 sex partner per year >1 sex partners per year
HPV (+) HPV (–) HPV (+) HPV (–) HPV (+) HPV (–)
21–25 1 0 6 22 2 6
26–30 2 4 17 50 7* 2
31–35 0 5 18 5 3 7
36–40 2 2 20 50 3 3
³41 1 1 21 45 0 4
*(÷2=10.08; p=0.001)
Fig. 1. Age-specific prevalence of HR-HPV infection in men from
north-eastern Croatia.
Fig. 2. HPV genotype distribution in men from north-eastern
Croatia.
Fig. 3. Age-specific distribution of HPV genotypes in men from
north-eastern Croatia.
were not detected in older age: HPVs 35, 18 and 66 were
not found in men older than 36 while HPVs 35, 84, 66
and 31 were not found in 36–40 year old men.
Concomitant infections with multiple HPV genotypes
were detected in 61% of HR HPV-infected participants of
the study. The highest prevalence of multiple HPV infec-
tions was found in 31–35 years old and in men older than
41 years (80% and 60%, respectively). The latter age
group also showed a significantly higher prevalence of
multiple infections than single infections. Multiple infec-
tions were less frequent in other age categories: 57% in
21–25 year old men, 53% in 26–30 years old men and 50%
in 36–40 year old men (Figure 4).
Risk factors for HPV infection
Table 1 summarizes possible risk factors for HPV in-
fection (age, marital status, smoking and sexual habits,
and income) that were investigated in this study. Statisti-
cal analysis confirmed that one of them – having more
than 1 sexual partner per year – was statistical margin-
ally significant associated with HR HPV infection (c2=
3.37; p=0.053). When analysed by age group, 26–30 year
old men with more than one sexual partner per year had
significantly higher HR HPV infection rate (c2=10.08;
p=0.001) when compared to men of the same age with
one sexual partner/year (Table 2). Other risk factors
such as age, marital status, smoking and income were




Between 2009 and 2011, one third of 330 men from
north-east Croatia whose genital swabs passed PCR qua-
lity control were infected with HR HPV. This was higher
than in two previous studies of men in central and west
Croatia: the first showed that 14.1% of 581 men from
Zagreb and Rijeka were infected between 2006 and
20085, the second one, that 21% of 100 men from Zagreb
were infected between 1996 and 20007. Two reasons may
explain the higher HR HPV prevalence in men from our
study: firstly, a potentially higher risk of our study popu-
lation for HPV infection as all participants underwent a
self – initiated STD screening, and secondly a higher
number of different HR HPV genotypes analysed8.
Genital HPV prevalence in men across the world var-
ies widely from 2 to 93%9,10. This variation is not only
due to the true, region-specific HPV prevalence but also
to differences in study design and methods. For instance,
different sampling techniques give different HPV pre-
valences: more HPV can be detected in external genitals
(glans/corona, shaft, and scrotum) than in anal samples,
semen, or urine11–14. Moreover, samples from the ure-
thral meatus can contain about half of HPV compared to
those from external genitals5. Different approaches in
genital sampling may also explain the relatively high-
-proportion of inadequate specimens (21%) in this study
– all of the inadequate samples were swabs from urethral
canals collected by general practitioners. Other studies
confirmed that testing multiple genital sites compared to
sampling from one genital site in men decreased the
number of inadequate, b-globin negative samples for
HPV testing by PCR technique5,14,15.
Among studies that used similar methods and target
populations-a PCR-based detection of HPV infection in
the genital swabs of attendees of STD clinics – the preva-
lence of HR HPV in men in this study (32%) was compa-
rable to men from Florida and Arizona (29.2% in hetero-
sexual men including STD attendees) but higher than in
STD attendees from British Columbia (24%), Denmark
(12.6%), Arizona (12%), and China (4.3%)12,16–21. More-
over, as a relatively small number of men less than 20
years of age participated in our survey (12 vs. 51–117
participants in other age groups), the true HR HPV prev-
alence in STD attendees of our County may be even
higher than 37.5%.
Age-specific distribution of HR HPV infection
Compared to the U-shaped age-specific HPV preva-
lence curve reported by others17, the HR HPV prevalence
in men from north-east Croatia showed the highest peak
in men younger than 20 years (37.5%) and in 36–40 years
old men (36.6%) followed by a slow decline with increas-
ing age: from 36.4% (in 21–25 year old men) to 27.8% (in
31–35 year old men). Whether other regions in Croatia
show a similar age-specific HPV distribution in men re-
mains to be determined. Other studies showed similar
age-associated peaks of HR HPV infection in men: in
STD clinic attendees from Denmark, the highest HR
HPV prevalence was detected in 18–24 year old men
(23.3%); in men attending vasectomy clinics in Mexico,
the highest prevalence was in men <25 years (10.6%); in
HIV-negative homosexual men from several USA cities,
the highest HR HPV prevalence was in 30–34 year old
men (30%)20,22,23. Nevertheless, not all of these results
may be comparable as different target populations were
analyzed.
The highest prevalence of HR HPV in our study was
detected in men £20 years (37.5%). One reason for this
might be their low number – while we recruited between
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Fig. 4. Age-specific prevalence of single and multiple HPV infec-
tion in men from north-east Croatia.
51 to 117 men in other age categories, we only found 12
men younger than 20 years probably because they were
less likely to visit general practitioners and STD clinics
than older men. This small proportion of tested young
men in our study may have resulted in an overestimation
of HR HPV infection compared to other age groups. Ad-
ditionally, one third of men £20 years inaccurately com-
pleted their questionnaires and were disqualified. Such
behavior of young men has been reported before24. Thus,
further studies are necessary to accurately estimate the
true HR HPV prevalence in young men of north-east
Croatia.
HPV Genotype Distribution
HPVs 6 and 16 were the predominant LR and HR
HPV genotypes (24.2 and 17.8%, respectively) in men
from north-east Croatia (Figure 2). These levels are simi-
lar to those found in other Croatian men5–7,25. However,
HPV 6 prevalence in women from the same region was
much lower (1.3%, Bo{njak et al, in preparation). Higher
prevalence of HPV 6 in men may be caused by their
hand-to-genital transmission of LR-HPVs, as previously
reported26. Contrary to other studies in Croatia however,
we detected less HPV 18 (1.3 vs. 12.2%), more HPV 31
(3.8 vs 1.8%) and no HPV 33 (0 vs. 3.1%)5–7. Whether this
reflects a region-specific difference or is a consequence of
different methods used for the HPV genotyping.
Compared to studies in other countries, the low prev-
alence of HPV 18 in our study (1.3%) was similar to that
in heterosexual men in Mexico (1.7%) and USA (0.5%).
Also our HPV 51 prevalence (8.8%) was similar to that in
Mexico (6.6%) and France (8%)27. Similarly, the preva-
lences of HPVs 31, 35 and 66 (3.8%, 5% and 5%, respec-
tively) were similar to those in Brazil (4.2%, 3.4% and
6.5%, respectively)28.
Multiple HPV infections
More than half of HPV-positive men in our study
(61%) were infected with multiple HPV types (Figure 4).
This percentage was much higher than previously re-
ported for Croatian men (3–13%)5–7. This difference may
be in part caused by our more sensitive methodology
which allowed detection of 37 HPV types. Interestingly,
HPV-positive men between 31–35 years of age were sig-
nificantly more infected with multiple HPV types (80%)
than with single HPV types (20%). This may be a conse-
quence of their higher susceptibility to novel HPV infec-
tions and/or higher persistence of multiple HPV infec-
tions, as suggested previously29.
When compared to heterosexual men from other
countries, the prevalence of multiple HPV infection in
our region was higher to that of 18–24 year olds from
Kenya (59%)30, of 18–70 year olds from Brazil (36.2%)
and Mexico (23.8%)31, and higher than the 18–40 year
olds from Florida (27.2%)12. Considering the high preva-
lence of multiple HPV types in 31–35 year old men from
east-north Croatia, their sexual partners could have an
increased risk for HPV-related malignancies.
Risk factors associated with HPV infection
Sexual activity is a well-known risk factor for HPV
infection32. Indeed, we observed that having more than
one sexual partner/year was a significant risk factor for
HR HPV infection in men (Table 1). Contrary to other
countries that reported the highest sexual activity in
men of less than 25 years33,34, our study observed it in the
26–30 year old men (Table 2). This correlated with the
high peak of HR HPV prevalence in the same age cate-
gory (Figure 1).
Other possible risk factors not significantly associated
with HR HPV infection in men from Osijek-Baranja
County were age, smoking, marital status, condom use,
and income. This may be due to the relatively low num-
ber of participants in this study as smoking and condom
use has been previously associated with HPV infection35.
Conclusion
This was the first cross-sectional study that deter-
mined the age-specific prevalence and genotype distribu-
tion of HPV infection in men from north-east Croatia.
There are several limitations to this study: a low number
and potentially high-risk behavior of the participants,
unknown medical history of participants and their sex-
ual partners, and a relatively high proportion of inade-
quate samples. Nevertheless, this study showed strong
evidence of high HPV prevalence in men from Osijek-
-Baranja County: between 2009 and 2011, one third of
STD attendees were infected with at least one HR HPV
and of these, more than a half suffered from multiple
HPV infections.
The most efficient and cheapest way of decreasing the
occurrence of HPV-related disease burden is vaccination.
However, in Croatia, vaccination is expensive and not
covered by state insurance programs: only 50 women in
our County and no men were immunized against HPVs
6, 11, 16 and 18 between 2007 and 2011 (Epidemiology
Department, Institute of Public Health, Osijek, 2011).
For these reasons, asymptomatic infections with HR
HPV, especially in 21–30 year old men, remain the main
source of infection for their sexual partners. We hope
that this study will initiate further research on HPV
prevalence in Croatian men, increase public awareness of
safe sex practices and make vaccination more accessible.
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PREVALENCIJA VISOKORIZI^NIH LJUDSKIH PAPILOMA VIRUSA (HR HPV) I RASPODJELA
HPV GENOTIPOVA U GENITALNIH UZORAKA KOD MU[KARACA OSJE^KO-BARANJSKE
@UPANIJE
S A @ E T A K
U Osje~ko-baranjskoj `upaniji ovo je prvo presje~no istra`ivanje prevalencije visokorizi~nih ljudskih papiloma virusa
(HR HPV, prema engl. High risk Human Papillomavirus) i raspodjele HPV-a u populaciji asimptomatskih heteroseksua-
laca. U periodu od 2009. do 2011. godine, 330 mu{karaca je ispitano na spolno prenosive bolesti. Brisevi spolnog po-
dru~ja su testirani AMPLICOR HPV testom i genotipizirani LINEAR ARRAY HPV testom za genotipizaciju. Kod tre-
}ine mu{karaca utvr|ena je infekcija s jednim HPV-om (32%) dok je u vi{e od polovice utvr|ena infekcija s vi{e virusa
HPV-a (61%). Najvi{a HR HPV prevalencija je utvr|ena u dobnoj skupini mla|oj od 20 godina (37,5%), dok je najni`a u
dobnoj skupini od 31 do 35 godina (27,8%). Odre|ena je raspodjela HPV genotipova HPV 6 (24%), 16 (17,8%), 51 (9%),
52 (6%), 35, 55, 66, 84 (svaki 5%), 31, 62 (svaki 4%), 39, 58, 59, 83 (svaki 2,5%), 56, 18, 53 i 54 (svaki 1,3%). Statisti~ki
zna~ajna povezanost utvr|ena je izme|u rizi~nog spolnog pona{anja (>1 spolnog partnera/godi{nje) u dobnoj skupini
od 26 do 30 godina starosti (p=0,001). Zbog visoke prevalencije HR HPV-a kod mu{karaca Osje~ko-baranjske `upanije i
rizika prijenosa na `ene opravdano je sustavno provo|enje informiranja javnosti o spolno prenosivom HPV-u kao i
pokretanje programa cijepljenja mla|e populacije mu{karaca i `ena.
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